First-Degree Relative Risk: In Utero Levetiracetam and Valproate Exposure

First-degree relative risk: in utero levetiracetam and valproate exposure.

Levetiracetam vs sodium valproate

2011;76;383 Neurology R. Shallcross, R.L. Bromley, B. Irwin, et al. sodium valproate Child development following in utero exposure : Levetiracetam vs May 5, 2011 This information is current as of http://www.neurology.org/content/76/4/383.full.html located on the World Wide Web at: The online version of this article, along with updated information and services, is rights reserved. Print ISSN: 00...

First trimester in utero exposure to methylphenidate.

Methylphenidate is a centrally acting sympathomimetic used for the treatment of attention deficit/hyperactivity disorder in children and adolescents and for narcolepsy in adults. Despite the growing use among adult women, no reliable data on the prevalence of use during pregnancy have been published, and safety during pregnancy has not been established. We systematically reviewed available data...

Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero.

An unselected series is presented of 17 infants born to epileptic mothers and exposed to sodium valproate during pregnancy. Nine infants had minor abnormalities and of these infants five also had major malformations, described as the 'fetal valproate syndrome'. The most frequent malformation was congenital heart disease. Nine of the infants had manifestations of withdrawal, such as irritability...

Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate.

AIMS To define, in a prospective study, the risk of hypoglycaemia-defined as blood glucose concentration < 1.8 mmol/l-in term infants exposed in utero to valproate and to describe the withdrawal symptoms. METHODS Twenty epileptic women were treated with valproate only during pregnancy and two were treated with valproate and carbamazepine. In the first trimester, the daily median dose of valpr...